Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced topline results from its Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA